Phase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC
/in Clinical Trial, Metastatic/by MaxEfficacy and Safety of Combination ARSI, Denosumab, and Local Radiotherapy in Poly-Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxAZD6621: A T-Cell Therapy Targets Hidden Prostate Cancer Driver
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2: Tulmimetostat + ARPI Combo for mHSPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 2 Trial for Sacituzumab Tirumotecan and Tagitanlimab Combo
/in Clinical Trial, Metastatic, Phase 2/by MaxTJ101 Enters Testing for Advanced Prostate Cancer Patients
/in Clinical Trial, Metastatic, Phase 1/by MaxOST-504: A Novel Immunotherapy Targeting Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025